Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.

PLoS One · 2016 · PMC4873225 · PMID 27196083

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantp≤0.001actually significant

When the two large groups of RP samples (benign RP-B and malignant RP-PCa) were compared with each other, most of the differences were statistically still highly significant (p≤0.001), except for RHOU , LMNB1 and PLA2G7 , indicating the stronger impact of detectable cancer tissue on biomarker expression patterns compared to likely field effects.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.